SUNMAO Medical's First Product, M1 Multifunctional synthesis module, Receives EU’s CE Certification

Recently, Sunmao Medical has reached an important international milestone: SUNMAO Medical's Product, M1 Multifunctional synthesis module, R...

MORE >>

Norroy's two prostate cancer nuclear drug IND applications were approved by FDA

Recently, the two new drug clinical trial (IND) applications submitted by Nuoyu Medicine to the FDA for the original theranostics integrated nu...

MORE >>

Norroy's first original nuclear drug for prostate cancer was approved for clinical trials in China

Recently, Norroy's independent innovative radiation therapy drug 177Lu-NY108(NYM032) injection has been granted clinical trial approval, ha...

MORE >>

Norroy's first original nuclear drug for Renal cancer was approved for clinical trials in both China and US

Following the FDA approval, the radiological diagnostic drug 68Ga-NY104(NYM005), which was fully self-developed by Norroy, was approved clinical t...

MORE >>

Sunmao Medical on the international journal of Annals of Nuclear Medicine (ANM), the international influence increased greatly!

In December 2023, Development and application of a fully automatic multi-function cassette module Mortenon M1 for radiopharmaceutical synthesis...

MORE >>

Sunmao medical radiation safety permit approved

In November 2023, Wuxi Sunmao Medical Technology Co., LTD. (hereinafter referred to as "Sunmao"), a subsidiary of Norroy, offici...

MORE >>

Norroy’s renal cancer pipeline 18F-NY104 entered the first Ph0 clinical trial

Recently, 18F-NY104 diagnostic nuclear drug, the second-generation molecule in the global innovative integrated pipeline independently develope...

MORE >>

Norroy Bioscience Establishes Operations Center at Nanjing

In October 2023, Norroy Nanjing Operation Center was officially established, settled in Yunfeng Building, Gulou District, Nanjing, rooted in th...

MORE >>

The first automated production line for nuclear medicine designed by Sunmao Medical was officially launched

In recent years, radiopharmaceuticals have shown strong clinical potential, and the clinical demand for nuclear drugs has shown an obvious ...

MORE >>

Norroy Bioscience Shines at the 36th Annual Congress of the European Association of Nuclear Medicine

From September 9 to September 13, Norroy first attended the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) in 2023...

MORE >>

Norroy’s IND application for 68Ga-NY104, an innovative nuclear drug for kidney cancer, has been approved by the FDA

In July 2023, Norroy Bioscience Co., LTD. (hereinafter referred to as Norroy) announced that the new drug clinical trial (IND) application for ...

MORE >>

Norroy Bioscience attended SNMMI 2023

The 2023 Annual Society of Nuclear Medicine and Molecular Imaging (SNMMI 2023) will take place June 24-27 in Chicago. The Congress offered more...

MORE >>